ELAB vs. ABVC, AVTX, ERNA, AKTX, MNPR, MIRA, GHSI, MBRX, AEZS, and ADXN
Should you be buying Elevai Labs stock or one of its competitors? The main competitors of Elevai Labs include ABVC BioPharma (ABVC), Avalo Therapeutics (AVTX), Eterna Therapeutics (ERNA), Akari Therapeutics (AKTX), Monopar Therapeutics (MNPR), MIRA Pharmaceuticals (MIRA), Guardion Health Sciences (GHSI), Moleculin Biotech (MBRX), Aeterna Zentaris (AEZS), and Addex Therapeutics (ADXN). These companies are all part of the "pharmaceutical preparations" industry.
ABVC BioPharma (NASDAQ:ABVC) and Elevai Labs (NASDAQ:ELAB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends.
In the previous week, Elevai Labs had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 6 mentions for Elevai Labs and 4 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.59 beat Elevai Labs' score of -0.42 indicating that Elevai Labs is being referred to more favorably in the news media.
ABVC BioPharma and Elevai Labs both received 0 outperform votes by MarketBeat users.
11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 22.2% of Elevai Labs shares are owned by institutional investors. 11.9% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Elevai Labs has higher revenue and earnings than ABVC BioPharma. Elevai Labs is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.
Elevai Labs has a net margin of -211.25% compared to Elevai Labs' net margin of -6,919.08%. ABVC BioPharma's return on equity of -225.32% beat Elevai Labs' return on equity.
Summary
Elevai Labs beats ABVC BioPharma on 8 of the 12 factors compared between the two stocks.
Get Elevai Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevai Labs Competitors List
Related Companies and Tools
